Three anti-platelet drugs used in combination are safe
Three drugs, each of which works in a different way, are used in anti-platelet therapy to help prevent restenosis (the reclogging of blood vessels after they have been cleared with percutaneous coronary intervention or PCI) or thrombosis (obstruction of an artery or vein by a blood clot). The use of these platelet inhibitory drugs -- cilostazol, clopidogrel and aspirin -- has resulted in a significant reduction of thrombotic complications in the primary and secondary prevention of heart attacks. But is it safe to use these medications together -- or in combination do they increase the risk of bleeding? And will patients comply with taking three pills?
In a poster session presented today at the American College of Cardiologys 54th Scientific Sessions in Orlando, Florida, Emory researchers say the answer to both questions is "yes".
The scientists analyzed data from the Cilostazol for RESTenosis (CREST) Trial, a randomized clinical trial testing the efficacy of cilostazol to prevent restenosis after PCI. Earlier results from CREST showed a 35% relative risk reduction in restenosis from 34% to 22% with cilostazol. The anti-thrombotic drugs Clopidogrel (75 mg daily for 30 days) and aspirin daily for 6 months were administered to all patients in the CREST trial while a total of 705 of these patients were randomized to cilostazol (354) or placebo (351) following successful angioplasty and stent implantation.
Twenty-nine patients experienced bleeding complications (17 major and 12 minor) but there was no significant difference in the rate of bleeding for patients who received aspirin plus clopidogrel plus cilostazol versus those who received aspirin plus clopidogrel. There was also no significant difference in type of bleeding (major or minor) experienced by these patients, no matter which drug therapy they were given.
"There was no evidence of increased risk of bleeding in patients treated with aspirin plus clopidogrel plus cilostazol and we also found that adherence to treatment was high," says Emory Heart Center cardiologist William Weintraub, MD, Director of the Emory Center for Outcomes Research, who participated in the study. "This is good news because all three anti-platelet medications work in somewhat different ways and in combination they may prove to have more efficacy."
In addition to Dr. Weintraub, the Emory research team included Jovonne K. Foster MS, Paul Kolm PhD, Grant T. Anderson, Karen M. Parker BS, John S. Douglas Jr. MD and Nancy VC Murrah RN,BSN. Drs. Douglas and Weintraub disclosed a commercial relationship with Otsuka American Pharmaceutical, Inc.
Sherry Baker | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Mapping the interaction of a single atom with a single photon may inform design of quantum devices
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...